Rivaroxaban patent expiration?

Patents for rivaroxaban (Xarelto) are jurisdiction-specific. There isn’t a single global expiration date. In short:

- The core composition-of-matter patents for rivaroxaban have expired in many major markets (US, EU) by the mid- to late-2010s, but there can be term extensions or pediatric exclusivities that push certain dates out.
- There are still other patents and patent families around uses (e.g., stroke prevention in atrial fibrillation), dosing regimens, and formulations in some regions, which can extend protection in those areas.
- Regulatory data exclusivity and other market protections can delay generic entry even after patent expiry.

If you want a precise date, tell me the jurisdiction (e.g., United States, European Union, United Kingdom, India, etc.) and whether you care about:
- composition-of-matter patents only, or
- use/formulation/method-of-use patents as well.

I can then point you to the specific patent families and provide approximate expiry years (and the relevant patent numbers) from official databases (USPTO, EPO, Google Patents, etc.).